Conjupro Biotherapeutics, Inc.
Clinical trials sponsored by Conjupro Biotherapeutics, Inc., explained in plain language.
-
Experimental lymphoma drug CPO107 tested in small early trial
Disease control TerminatedThis early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited informati…
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental cancer drug CPO-100 trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC